December 3, 2021 10:55 AM EST

Biospecimen M&A: Discovery acquires Albert Li's hepatocyte project; PhIII trial on Bayer's Nubeqa reached primary endpoint

Josh Sullivan

Paul Schloesser

Associate Editor

Discovery Life Sciences has acquired what claims to be the Maryland-based host of the world’s largest hepatocyte inventory, known as IVAL, to help researchers select …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biospecimen M&A: Discovery acquires Albert Li's hepatocyte project; PhIII trial on Bayer's Nubeqa reached primary endpoint

Josh Sullivan

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

Biospec­i­men M&A: Dis­cov­ery ac­quires Al­bert Li's he­pa­to­cyte project; PhI­II tri­al on Bay­er's Nube­qa reached pri­ma­ry end­point

Associate Editor

Sign up to read this article for free.

Biospecimen M&A: Discovery acquires Albert Li's hepatocyte project; PhIII trial on Bayer's Nubeqa reached primary endpoint